Primary breast cancer
Conditions
Interventions
A chemotherapy treatment plan in which drugs are given with less time between treatments than in a standard chemotherapy treatment plan.
Sponsors
Nagoya University Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients with primary breast cancer who had been decided to treat epirubicin and cyclophosphamide in neoadjuvant or adjuvant setting. Additional eligibility criteria for enrollement include: having no evidence of metastatic disease, having the following laboratory values: absolute neutrophil count >=1500/mm3, hemoglobin >=9.0g/dl, platelets >=100,000/mm3, aspartate aminotransferase and alanine aminotransferase <=100IU/ml, serum bilirubin <=1.5mg/dl, serum creatinine <=1.5mg/dl, being no cardiac dysfunction on ECG and US, having an Eastern Cooperative Oncoligy Group performance status of O or 1, and having been written informed consent.
Exclusion criteria
Exclusion criteria: Patients with active infection need to treat systemic therapy, nursing, mental disorder, or other uncontrolled medical conditions are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative dose intensity | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events To evaluate the accumulation of pegfirugrasutim | — |
Countries
Japan
Contacts
Public ContactSachi Morita
Nagoya University Hospital Department of Clinical Oncology and Chemotherapy
Outcome results
None listed